CRIS, Curis (formerly CBMI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI)

CRIS 1.150

+2.7%

Nov 25 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Boyce Burge who wrote (46)	6/10/1997 3:21:00 PM
From: Harold Engstrom	of 668

I was at the Biogen annual meeting last week and OP-1 was discussed as part of Biogen's pipeline - the renal failure indication as opposed to the orthopedic indications. I have read where Biogen may end up paying as much as $110M for OP-1 for renal failure if the drug hits specified milestones. All of CBM is currently capitalized for $250M or less...is there any reason Biogen wouldn't want to purchase CBM at these prices? Is there anything keeping Biogen or another company from buying them out?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next